Руководство по диагностике, профилактике и лечению сердечно-сосудистых осложнений противоопухолевой терапии. Части VI–VII

1. Green KB, Silverstein RL. Hypercoagulobility in cancer. Hemat Onc Clin N Am 1996; 10: 499–530.
2. Hillen HF. Thrombosis in cancer patients. ESMO Ann Oncol 2000; 11 (Suppl. 3): 273–6.
3. Levine MN, Lee AY, Kakkar AK. Thrombosis and cancer. American Society of Clinical Oncology, 41 Annual Meeting, 2005, May 13–17; р. 748–77.
4. Bromberg ME, Cappello M. Cancer and blood coagulation: molecular aspects. Cancer 1999; 3: 132–8.
5. Falanga A, Tickles FR. Pathophysiology of the thrombotic state in the cancer patient. Semin Thromb Haemostas 1999; 25: 173–82.
6. Windecker S, Kolh P, Alfonso F et al. 2014 ESC/EACTS Guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J 2014; 35: 2541–619.
7. Roffi M, Patrono C, Collet JP et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J 2016; 37: 267–315.
8. Steg PG, James SK, Atar D et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 2012; 33: 2569–619.
9. Moore RA, Adel N, Riedel E et al. High incidence of thromboembolic events in patients treated with cisplatin-based chemotherapy: a large retrospective analysis. J Clin Oncology 2011; 29: 3466–473.
10. Zamorano JL, Lancellotti Р, Munoz DR et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines. Eur Heart J 2016; 37: 2768–801.
11. Haugnes HS, Wethal T, Aass N et al. Cardiovascular risk factors and morbidity in long-term survivors of testricular cancer: a 20-year follow-up study. J Clin Oncology 2010; 28: 4649–57.
12. Huddart RA, Norman A, Shahidi M et al. Cardiovascular disease as long-termcomplication of treatment for testicular cancer. J Clin Oncology 2003; 21: 1513–23.
13. Cameron D, Brown J, Dent R et al. Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomized, phase 3 trial. Lancet Oncol 2013; 14: 933–42.
14. Levine GN, Bates ER, Bittl JA et al. 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease. Circulation 2016; 134: 123–55.
15. Khorana AA, Connolly GC. Assessing risk of venous thromboembolism in the patient with cancer. Clin Oncol 2009; 27: 4839–47.
16. Андрияшкин В.В., Кириенко А.И., Явелов И.С. и др. Российские клинические рекомендации по профилактике и лечению венозных тромбоэмболических осложнений у онкологических больных. 2014; с. 10–1. / Andriiashkin V.V., Kirienko A.I., Iavelov I.S. i dr. Rossiiskie klinicheskie rekomendatsii po profilaktike i lecheniiu venoznykh tromboembolicheskikh oslozhnenii u onkologicheskikh bolnykh. 2014; s. 10–1. [in Russian]
17. Khorana AA, Carrier M, Garcia DA et al. Guidance for the prevention and treatment of cancer-associated venous thromboembolism. J Tromb Thrombolysis 2016; 41: 81–91.
18. Kucher N, Koo S, Quiroz R et al. Electronic Alerts to Prevent Venou Thromboembolism among Hospitalized Patients. N Engl J Med 2005; 352: 969–77.
19. Lyman GH, Khorana AA, Kuderer NM et al. Venous thromboembolism prophilaxis and treatment in patients with cancer; American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 2013; 31 (17): 2189–204.
20. Чазова И.Е., Тюляндин С.А., Виценя М.В. и др. Руководство по диагностике, профилактике и лечению сердечно-сосудистых осложнений противоопухолевой терапии. Часть I. Системные гипертензии. 2017; 14 (3): 6–20. / Chazova I.Ye., Tyulyandin S.A., Vicenia M.V. et al. Clinical Manual for Diagnosis, Prevention and Treatment of Cardiovascular Complications of Cancer Therapy. Part I. Systemic Hypertension. 2017; 14 (3): 6–20. [in Russian]
21. Khorana AA, Kuderer NM, Culakova E. Development and Validation of a predictive model for chemotherapy-associated thrombosis. Blood 2008; 111 (10): 4902–7.
22. Khorana AA. Risk assessment and profilaxis for VTE in cancer patients. Natl Compr Canc Netw 2011; 9: 789–97.
23. Watson HG et al. Guideline on aspects of cancer-related venous thrombosis. Br J Haematol 2015; 170: 640–8.
24. Schulman S, Goldhaber SZ, Kearon C et al. Treatment with dabigatran or warfarin in patients with venous thromboembolism and cancer. Thromb Haemost 2015; 114: 150–7.
25. Prins MH, Lensing AW, Brighton TA et al. Oral rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of symptomatic venous thromboembolism in patients with cancer (EINSTEIN-DVT and EINSTEIN-PE): a pooled subgroup analysis of two randomised controlled trials. Lancet Haematol 2014; 1 (1): e37–46.
26. Vedovati MC, Germini F, Agnelli G, Becattini C. Direct oral anticoagulants in patients with VTE and cancer: a systematic review and meta-analysis. Chest 2015; 147 (2): 475–83.
27. Gerotziafas GT, Mahe I, Elalamy I. New orally active anticoagulant agents for the prevention and treatment of venous thromboembolism in cancer patients. Ther Clin Risk Manag 2014; 10: 423–36.
28. Kearon C, Akl EA, Ornelas J et al. Antithrombotic Therapy for VTE Disease. Chest Guidelines and Expert Panel Report. Chest 2016; 149 (2): 315–52.
29. Gagliardi G, Constine LS, Moiseenko V et al. Radiation Dose-Volume Effects in the Heart. Int J Radiat Oncol Biol Phys 2010; 76 (3; Suppl.): 77–85.
30. Aleman BMP, van den Belt-Dusebout AW, Klokman WJ et al. Long-term cause-specific mortality of patients treated for Hodgkin’s disease. J Clin Oncol 2003; 21: 3431–9.
31. Darby SC, Cutter DJ, Boerma M et al. Radiation-related heart disease: current knowledge and future prospects. Int J Radiat Oncol Biol Phys 2010; 76: 656–65.
32. Wei X, Liu HH, Tucker SL et al. Risk factors for pericardial effusion in inoperable esophageal cancer patients treated with definitive chemoradiation therapy. Int J Radiat Oncol Biol Phys 2008; 70: 707–14.
33. Jaworski C, Mariani JA, Wheeler G, Kaye DM. Cardiac complications of thoracic irradiation. J Am Coll Cardiol 2013; 61: 2319–28.
34. Aleman BM, van den Belt-Dusebout AW, De Bruin ML et al. Late cardiotoxicity after treatment for Hodgkin lymphoma. Blood 2007; 109: 1878–86.
35. Taylor CW et al. Cardiac exposures in breast cancer radiotherapy: 1950’s–1990’s. Int J Radiat Oncol Biol Phys 2007; 69: 1484–95.
36. Cuzick J, Stewart H, Peto R et al. Overview of randomized trials of postoperative adjuvant radiotherapy in breast cancer. Cancer Treat Rep 1987; 71: 15–29.
37. Paszat LF, Mackillop WJ, Groome PA et al. Mortality from myocardial infarction after adjuvant radiotherapy for breast cancer in the surveillance, epidemiology, and end-results cancer registries. J Clin Oncol 1998; 16: 2625–31.
38. Early Breast Cancer Trialists’ Collaborative Group. Effects of radiotherapy and surgery in early breast cancer. An overview of the randomized trials. N Engl J Med 1995; 333 (22): 1444–55.
39. Clarke M, Collins R, Darby S et al. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 366: 2087–106.
40. Giordano SH, Kuo YF, Freeman JL et al: Risk of cardiac death after adjuvant radiotherapy for breast cancer. J Natl Cancer Inst 2005; 97 (6): 419–24.
41. Hooning M, Botma A, Aleman B et al. Long-term risk of cardiovascular disease in 10-year survivors of breast cancer. J Natl Cancer Inst 2007; 99: 365–75.
42. Borger JN, Hooning MJ, Boersma LJ et al. Cardiotoxic effects of tangential breast irradiation in early breast patients: The role of irradiated heart volume. Inst J Radiat Oncol Biol Phys 2007; 69 (4): 1131–8.
43. Darby SC, McGale P, Taylor CW, Peto R. Long-term mortality from heart disease and lung cancer after radiotherapy for early breast cancer: prospective cohort study of about 300,000 women in US SEER cancer registries. Lancet Oncol 2005; 6: 557–65.
44. Early Breast Cancer Trialists Collaborative Group (EBCTCG), Darby S, McGale P, Correa C et al. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet 2011; 378 (9804): 1707–16.
45. Patt DA, Goodwin JS, Kuo YE et al. Cardiac morbidity of adjuvant radiotherapy for breast cancer. J Clin Oncol 2005; 23 (30): 7475–82.
46. Wright GP, Drinane JJ. Left-Sided Breast Irradiation does not Result in Increased Long-Term Cardiac-Related Mortality Among Women Treated with Breast-Conserving Surgery. Ann Surg Oncol 2016, 23: 1117–22.
47. Schultz-Hector S, Trott KR. Radiation-induced cardiovascular diseases: is the epidemiologic evidence compatible with the radiobiologic data. Int J Radiat Oncol Biol Phys 2007; 67: 10–8.
48. Wu W, Masri A, Popovic ZB et al. Long-term survival of patients with radiation heart disease undergoing cardiac surgery: a cohort study. Circulation 2013; 127: 1476–84.
49. Hancock S, Tucker M, Hoppe R. Factors affecting late mortality from heart disease after treatment of Hodgkin’s disease. JAMA 1993; 270: 1949–55.
50. Carver JR, Shapiro CL, Ng A et al. ASCO Cancer Survivorship Expert Panel. American Society of Clinical Oncology clinical evidence review on the ongoing care of adult cancer survivors: cardiac and pulmonary late effects. J Clin Oncol 2007; 25: 3991–4008.
51. Meyer R, Gospodarowicz M, Connors J et al. NCIC Clinical Trials Group, Eastern Cooperative Oncology Group. ABVD alone versus radiation-based therapy in limited-stage Hodgkin’s lymphoma. N Engl J Med 2012; 366: 399–408.
52. Lee CK, Aeppli D, Nierengarten ME. The need for long-term surveillance for patients treated with curative radiotherapy for Hodgkin’s disease: University of Minnesota experience. Int J Radiat Oncol Biol Phys 2000; 48: 169–79.
53. Lancellotti P, Nkomo VT, Badano LP et al. European Society of Cardiology Working Groups on Nuclear Cardiology and Cardiac Computed Tomography and Cardiovascular Magnetic Resonance, American Society of Nuclear Cardiology, Society for Cardiovascular Magnetic Resonance, Society of Cardiovascular Computed Tomography. Expert consensus for multi-modality imaging evaluation of cardiovascular complications of radiotherapy in adults: a report from the European Association of Cardiovascular Imaging and the American Society of Echocardiography. Eur Heart J Cardiovasc Imaging 2013; 14: 721–40.
54. Ridker PM, Buring JE, Rifai N et al. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: The Reynolds score. J Am Med Assoc 2007; 297 (6): 611–9.
55. Darby SC, Ewertz M, McGalle P et al. Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med 2013; 368: 987–98.
56. Marhin W, Wai E, Tyldesley S. Impact of fraction size on cardiac mortality in women treated with tangential radiotherapy for localized breast cancer. Int J Radiat Oncol Biol Phys 2007; 69: 483–89.
57. Shapiro C, Hardenbergh P, Gelman R et al. Cardiac effects of adjuvant doxorubicin and radiation therapy in breast cancer patients. J Clin Oncol 1998; 16: 3493–501.
58. Hull MC, Morris CG, Pepine CJ, Mendenhall NP. Valvular Dysfunction and Carotid, Subclavian, and Coronary Artery Disease in Survivors of Hodgkin Lymphoma Treated With Radiation Therapy. JAMA 2003; 290 (21): 2831–37.
59. Marks LB, Yu X, Prosnitz RG et al. The incidence functional consequences of RT-associated cardiac perfusion defects. Int J Radiat Oncol Biol Phys 2005; 63 (1): 214–23.
60. Van Nimwegen FA, Schaapveld M, Janus CP et al. Cardiovascular disease after Hodgkin lymphoma treatment: 40-year disease risk. JAMA Intern Med 2015; 175: 1007–17.
61. Paszat LF, Mackillop WJ, Groome PA. Mortality from myocardial infarction following postmastectomy radiotherapy for breast cancer: A population-based study in Ontario, Canada. Inst J Radiat Oncol Biol Phys 1999; 43 (2): 755–61.
62. King V, Constine L, Clark D et al. Symptomatic coronary artery disease after mantle irradiation for Hodgkin’s disease. Int J Radiat Oncol Biol Phys 1996; 36: 881–9.
63. Heidenreich P, Kapoor J. Radiation induced heart disease: systemic disorders in heart disease. Heart 2009; 95: 252–8.
64. Harris EE, Correa C, Hwang WT. Late cardiac mortality and morbidity in early-stage breast cancer patients after breast-conservation treatment. J Clin Oncol 2006; 24 (25): 4100–6.
65. Baker JE, Moulder JE, Hopewell JW. Radiation as a risk factor for cardiovascular disease. Antioxid Redox Signal 2011; 15: 1945–56.
66. Taunk NK, Haffty BG, Kostis JB, Goyal S. Radiation-induced heart disease: pathologic abnormalities and putative mechanisms. Front Oncol 2015; 5: 39.
67. Boerma M, Hauer-Jensen M. Preclinical research into basic mechanisms of radiation-induced heart disease. Cardiol Res Pract 2011. DOI: 10.4061/2011/858262
68. Stewart F, Hoving S, Russell N. Vascular damage as an underlying mechanism of cardiac and cerebral toxicity in irradiated cancer patients. Radiat Res 2010; 174: 865–9.
69. Yusuf S, Sami S, Daher I. Radiation-induced heart disease: a clinical update. Cardiol Res Pract 2011; Article ID 317659.
70. Stewart F, Heeneman S, Te Poele J et al. Ionizing radiation accelerates the development of atherosclerotic lesions in ApoE2/2 mice and predisposes to an inflammatory plaque phenotype prone to hemorrhage. Am J Pathol 2006; 168: 649–58.
71. Hardenbergh PH, Munley MT, Bentel GC et al. Cardiac perfusion changes in patients treated for breast cancer with radiation therapy and doxorubicin: preliminary results. Int J Radiat Oncol Biol Phys 2001; 49: 1023–8.
72. Gomez DR, Yusuf SW, Munsell M et al. A Prospective Exploratory Analysis of Cardiac Biomarkers and Electrocardiogram Abnormalities in Patients Receiving Thoracic Radiation Therapy with High-Dose Heart Exposure. J Thorac Oncol 2014; 9 (10): 1554–60.
73. Erven K, Florian A, Slagmolen P, Sweldens C et al. Subclinical cardiotoxicity detected by strain rate imaging up to 14 months after breast radiation therapy. Int J Radiat Oncol Biol Phys 2013; 85 (5): 1172–8.
74. Armstrong GT, Joshi VM, Ness KK et al. Comprehensive echocardiographic detection of treatment-related cardiac dysfunction in adult survivors of childhood cancer: results from the St. Jude Lifetime Cohort Study. J Am Coll Cardiol 2015; 65: 2511–22.
75. Nagueh S, Appleton C, Gillebert T et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography. Eur J Echocardiogr 2009; 10: 165–93.
76. Constine L, Schwartz R, Savage D et al. Cardiac function, perfusion, and morbidity in irradiated long-term survivors of Hodgkin’s disease. Int J Radiat Oncol Biol Phys 1997; 39: 897–906.
77. DePasquale EC, Nasir K, Jacoby DL. Outcomes of adults with restrictive cardiomyopathy after heart transplantation. J Heart Lung Transplant 2012; 31 (12): 1269–75.
78. McGale P, Darby SC, Hall P et al. Incidence of heart disease in 35,000 women treated with radiotherapy for breast cancer in Denmark and Sweden. Radiother Oncol 2011; 100: 167–75.
79. Virmani R, Farb A, Carter AJ, Jones RM. Comparative pathology: radiation-induced coronary artery disease in man and animals. Semin Interv Cardiol 1998; 3: 163–72.
80. Brosius FC 3rd, Waller BF, Roberts WC. Radiation heart disease. Analysis of 16 young (aged 15 to 33 years) necropsy patients who received over 3,500 rads to the heart. Am J Med 1981; 70: 519–530.
81. Veinot JP, Edwards WD. Pathology of radiation-induced heart disease: a surgical and autopsy study of 27 cases. Hum Pathol 1996; 27: 766–73.
82. McEniery PT, Dorosti K, Schiavone WA et al. Clinical and angiographic features of coronary artery disease after chest irradiation. Am J Cardiol 1987; 60: 1020–4.
83. Hering D, Faber L, Horstkotte D. Echocardiographic features of radiation-associated valvular disease. Am J Cardiol 2003; 92: 226–30.
84. Brouwer CA, Postma A, Hooimeijer HL et al. Endothelial damage in long-term survivors of childhood cancer. J Clin Oncol 2013; 31: 3906–13.
85. Correa CR, Litt HI, Hwang WT et al. Coronary artery findings after left-sided compared with right-sided radiation treatment for earlystage breast cancer. J Clin Oncol 2007; 25: 3031–7.
86. Storey MR, Munden R, Strom EA et al. Coronary artery dosimetry in intact left breast irradiation. Cancer J 2001; 7: 492–7.
87. Van Nimwegen FA, Schaapveld M, Cutter DJ et al. Radiation dose-response relationship for risk of coronary heart disease in survivors of Hodgkin lymphoma. J Clin Oncol 2016; 34: 235–43.
88. De Haas EC, Oosting SF, Lefrandt JD et al. The metabolic syndrome in cancer survivors. Lancet Oncol 2010; 11: 193–203.
89. Oeffinger KC, Mertens AC, Sklar CA et al. Childhood Cancer Survivor Study. Chronic health conditions in adult survivors of childhood cancer. N Engl J Med 2006; 355: 1572–82.
90. Orzan F, Brusca A, Conte MR et al. Severe coronary artery disease after radiation therapy of the chest and mediastinum: clinical presentation and treatment. Br Heart J 1993; 69: 496–500.
91. Vijayakumar S, Rosenberg I, Spelbring D, Brandt T. Estimation of doses to heart, coronary arteries, and spinal cord in mediastinal irradiation for Hodgkin’s disease. Med Dosim 1991; 16: 237–41.
92. Prosnitz RG, Hubbs JL, Evans ES et al. Prospective assessment of radiotherapy-associated cardiac toxicity in breast cancer patients: analysis of data 3 to 6 years after treatment. Cancer 2007; 110: 1840–50.
93. Gyenes G, Fornander T, Carlens P et al. Detection of radiation-induced myocardial damage by technetium-99 m sestamibi scintigraphy. Eur J Nucl Med 1997; 24: 286–92.
94. Haugnes HS, Wethal T, Aass N et al. Cardiovascular risk factors and morbidity in long-term survivors of testicular cancer: a 20-year follow-up study. J Clin Oncol 2010; 28: 4649–57.
95. Malanca M, Cimadevilla C, Brochet E et al. Radiotherapy-induced mitral stenosis: a three-dimensional perspective. J Am Soc Echocardiogr 2010; 23 (108): e101–102.
96. Plana JC, Galderisi M, Barac A et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging 2014; 15: 1063–93.
97. Carlson RG, Mayfield WR, Normann S, Alexander JA. Radiation-associated valvular disease. Chest 1991; 99: 538–45.
98. Glanzmann C, Huguenin P, Lutolf UM et al. Cardiac lesions after mediastinal irradiation for Hodgkin’s disease. Radiother Oncol 1994; 30: 43–54.
99. Brand MD, Abadi CA, Aurigemma GP et al. Radiation-associated valvular heart disease in Hodgkin’s disease is associated with characteristic thickening and fibrosis of the aortic-mitral curtain. J Heart Valve Dis 2001; 10: 681–5.
100. Katz NM, Hall AW, Cerqueira MD. Radiation induced valvulitis with late leaflet rupture. Heart 2001; 86: E20.
101. Pohjola-Sintonen S, Totterman KJ, Salmo M, Siltanen P. Late cardiac effects of mediastinal radiotherapy in patients with Hodgkin’s disease. Cancer 1987; 60: 31–7.
102. Cutter DJ, Schaapveld M, Darby SC et al. Risk of valvular heart disease after treatment for Hodgkin lymphoma. J Natl Cancer Inst 2015; 107: djv008.
103. Groarke JD, Nguyen PL, Nohria A et al. Cardiovascular complications of radiation therapy for thoracic malignancies: the role for noninvasive imaging for detection of cardiovascular disease. Eur Heart J 2014; 35: 612–23.
104. Vahanian A, Alfieri O, Andreotti F et al. Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC), European Association for Cardio-Thoracic Surgery (EACTS), Guidelines on the management of valvular heart disease (version 2012). Eur Heart J 2012; 33: 2451–96.
105. De Bruin ML, Dorresteijn LD, van’t Veer MB et al. Increased risk of stroke and transient ischemic attack in 5-year survivors of Hodgkin lymphoma. J Natl Cancer Inst 2009; 101: 928–37.
106. Yuan H, Gaber MW, Boyd K et al. Effects of fractionated radiation on the brain vasculature in a murine model: blood-brain barrier permeability, astrocyte proliferation, and ultrastructural changes. Int J Radiat Oncol Biol Phys 2006; 66: 860–6.
107. Louis EL, McLoughlin MJ, Wortzman G. Chronic damage to medium and large arteries following irradiation. J Can Assoc Radiol 1974; 25: 94–104.
108. Fajardo LF. The pathology of ionizing radiation as defined by morphologic patterns. Acta Oncol 2005; 44: 13–22.
109. Jurado JA, Bashir R, Burket MW. Radiation-induced peripheral artery disease. Catheter Cardiovasc Interv 2008; 72: 563–8.
110. Tendera M, Aboyans V, Bartelink ML et al. European Stroke Organisation, ESC Committee for Practice Guidelines. ESC Guidelines on the diagnosis and treatment of peripheral artery diseases: Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries: the Task Force on the Diagnosis and Treatment of Peripheral Artery Diseases of the European Society of Cardiology (ESC). Eur Heart J 2011; 32: 2851–906.
111. Fokkema M, den Hartog AG, Bots ML et al. Stenting versus surgery in patients with carotid stenosis after previous cervical radiation therapy: systematic review and meta-analysis. Stroke 2012; 43: 793–801.
112. Gujral DM, Shah BN, Chahal NS et al. Clinical features of radiation-induced carotid atherosclerosis. Clin Oncol (R Coll Radiol) 2014; 26: 94–102.
113. Adler Y, Charron P, Imazio M et al. European Society of Cardiology. 2015 ESC Guidelines for the diagnosis and management of pericardial diseases: the Task Force for the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology (ESC). Endorsed by: the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 2015; 36: 2921–64.
114. Stewart JR, Fajardo LF, Gillette SM, Constine LS. Radiation injury to the heart. Int J Radiat Oncol Biol Phys 1995; 31: 1205–11.
115. Applefeld MM, Wiernik PH. Cardiac disease after radiation therapy for Hodgkin’s disease: analysis of 48 patients. Am J Cardiol 1983; 51: 1679–81.
116. Maisch B, Ristic A, Pankuweit S. Evaluation and Management of Pericardial Effusion in Patients with Neoplastic Disease. Prog Cardiovasc Dis 2010; 53 (2): 157–63.
117. Welch TD, Ling LH, Espinosa RE et al. Echocardiographic diagnosis of constrictive pericarditis: Mayo Clinic criteria. Circ Cardiovasc Imaging 2014; 7: 526–34.
118. Bertog SC, Thambidorai SK, Parakh K et al. Constrictive Pericarditis: Etiology and Cause-Specific Survival After Pericardiectomy. J Am Coll Cardiol 2004; 43: 1445–52.
119. Ness KK, Armstrong GT. Screening for cardiac autonomic dysfunction among Hodgkin lymphoma survivors treated with thoracic radiation. J Am Coll Cardiol 2015; 65: 584–5.
120. Bentzen SM, Constine LS, Deasy JO. Quantitative Analyses of Normal Tissue Effects in the Clinic (QUANTEC): an introduction to the scientific issues. Int J Radiat Oncol Biol Phys 2010; 76 (Suppl. 3): S3–9.
121. Prosnitz RG, Chen YH, Marks LB. Cardiac toxicity following thoracic radiation. Semin Oncol 2005; 32 (2; Suppl. 3): S71–S80.
122. Louwe RJ, Wendling M, van Herk MB, Mijnheer BJ. Three-dimensional heart dose reconstruction to estimate normal tissue complication probability after breast irradiation using portal dosimetry. Med Phys 2007; 34: 1354–63.
123. McDonald MW, Godette KL, Whitaker DJ et al. Three-year outcomes of breast. intensity-modulated radiation therapy with. simultaneous integrated boost. Int J Radiat Oncol Biol Phys 2010; 77: 523–30.
124. Tan W, Liu D, Xue C et al. Anterior myocardial territory may replace the heart as organ at risk in intensity-modulated radiotherapy for left-sided breast cancer. Int J Radiat Oncol Biol Phys 2012; 82: 1689–97.
125. Baycan D, Karacetin D, Balkanay AY et al. Field-in-field IMRT versus 3D-CRT of the breast. Cardiac vessels, ipsilateral lung, and contralateral breast absorbed doses in patients with left-sided lumpectomy: a dosimetric comparison. Jpn J Radiol 2012; 30: 819–23.
126. Bruzzaniti V, Abate A, Pinnaro P et al. Dosimetric and clinical advantages of deep inspiration breath-hold (DIBH) during radiotherapy of breast cancer. J Exp Clin Cancer Res 2013; 32: 88.
127. Xu Q, Chen Y, Grimm J et al. Dosimetric investigation of accelerated partial breast irradiation (APBI) using CyberKnife. Med Phys 2012; 39: 6621–8.
128. Bartlett FR, Colgan RM, Donovan EM et al. HeartSpare Study (Stage IB): randomised comparison of a voluntary breath-hold technique and prone radiotherapy after breast conserving surgery. Radiother Oncol 2015; 114: 66–72.
129. Utehina O. Healthy tissue sparing postoperative radiotherapy for treatment of early stage breast cancer. Summary of the doctoral thesis. Riga, 2009; p. 32.
130. Трофимова О.П., Чебан О.И., Михина З.П. Кардиоваскулярные осложнения у больных РМЖ после органосохраняющего лечения. Мед. радиология и радиационная безопасность. 2015; 1: 33–8. / Trofimova O.P., Cheban O.I., Mikhina Z.P. Kardiovaskuliarnye oslozhneniia u bolnykh RMZh posle organosokhraniaiushchego lecheniia. Med. radiologiia i radiatsionnaia bezopasnost. 2015; 1: 33–8. [in Russian]
131. Piepoli MF, Hoes AW, Agewall S et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. DOI: 10.1093/eurheartj/ehw106
132. Ewer MS, Lenihan DJ. Left ventricular ejection fraction and cardiotoxicity: is our ear really to the ground? J Clin Oncol 2008; 26: 1201–3.
133. Lenihan DJ, Cardinale DM. Late cardiac effects of cancer treatment. J Clin Oncol 2012; 30: 3657–64.
134. Heidenreich PA, Hancock SL, Lee BK et al. Asymptomatic cardiac disease following mediastinal irradiation. J Am Coll Cardiol 2003; 42: 743–9.
135. Koppelmans V, Vernooij MW, Boogerd W et al. Prevalence of cerebral small-vessel disease in long-term breast cancer survivors exposed to both adjuvant radiotherapy and chemotherapy. J Clin Oncol 2015; 33: 588–93.
136. Copeland KA, Hosmane VR, Jurkovitz C et al. Frequency of severe valvular disease caused by mediastinal radiation among patients undergoing valve surgery in a community-based, regional academic medical center. Clin Cardiol 2013; 36: 217–21.
137. Machann W, Beer M, Breunig M et al. Cardiac magnetic resonance imaging findings in 20-year survivors of mediastinal radiotherapy for Hodgkin’s disease. Int J Radiat Oncol Biol Phys 2011; 79: 1117–23.

________________________________________________

1. Green KB, Silverstein RL. Hypercoagulobility in cancer. Hemat Onc Clin N Am 1996; 10: 499–530.
2. Hillen HF. Thrombosis in cancer patients. ESMO Ann Oncol 2000; 11 (Suppl. 3): 273–6.
3. Levine MN, Lee AY, Kakkar AK. Thrombosis and cancer. American Society of Clinical Oncology, 41 Annual Meeting, 2005, May 13–17; р. 748–77.
4. Bromberg ME, Cappello M. Cancer and blood coagulation: molecular aspects. Cancer 1999; 3: 132–8.
5. Falanga A, Tickles FR. Pathophysiology of the thrombotic state in the cancer patient. Semin Thromb Haemostas 1999; 25: 173–82.
6. Windecker S, Kolh P, Alfonso F et al. 2014 ESC/EACTS Guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J 2014; 35: 2541–619.
7. Roffi M, Patrono C, Collet JP et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J 2016; 37: 267–315.
8. Steg PG, James SK, Atar D et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 2012; 33: 2569–619.
9. Moore RA, Adel N, Riedel E et al. High incidence of thromboembolic events in patients treated with cisplatin-based chemotherapy: a large retrospective analysis. J Clin Oncology 2011; 29: 3466–473.
10. Zamorano JL, Lancellotti Р, Munoz DR et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines. Eur Heart J 2016; 37: 2768–801.
11. Haugnes HS, Wethal T, Aass N et al. Cardiovascular risk factors and morbidity in long-term survivors of testricular cancer: a 20-year follow-up study. J Clin Oncology 2010; 28: 4649–57.
12. Huddart RA, Norman A, Shahidi M et al. Cardiovascular disease as long-termcomplication of treatment for testicular cancer. J Clin Oncology 2003; 21: 1513–23.
13. Cameron D, Brown J, Dent R et al. Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomized, phase 3 trial. Lancet Oncol 2013; 14: 933–42.
14. Levine GN, Bates ER, Bittl JA et al. 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease. Circulation 2016; 134: 123–55.
15. Khorana AA, Connolly GC. Assessing risk of venous thromboembolism in the patient with cancer. Clin Oncol 2009; 27: 4839–47.
16. Andriiashkin V.V., Kirienko A.I., Iavelov I.S. i dr. Rossiiskie klinicheskie rekomendatsii po profilaktike i lecheniiu venoznykh tromboembolicheskikh oslozhnenii u onkologicheskikh bolnykh. 2014; s. 10–1. [in Russian]
17. Khorana AA, Carrier M, Garcia DA et al. Guidance for the prevention and treatment of cancer-associated venous thromboembolism. J Tromb Thrombolysis 2016; 41: 81–91.
18. Kucher N, Koo S, Quiroz R et al. Electronic Alerts to Prevent Venou Thromboembolism among Hospitalized Patients. N Engl J Med 2005; 352: 969–77.
19. Lyman GH, Khorana AA, Kuderer NM et al. Venous thromboembolism prophilaxis and treatment in patients with cancer; American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 2013; 31 (17): 2189–204.
20. Chazova I.Ye., Tyulyandin S.A., Vicenia M.V. et al. Clinical Manual for Diagnosis, Prevention and Treatment of Cardiovascular Complications of Cancer Therapy. Part I. Systemic Hypertension. 2017; 14 (3): 6–20. [in Russian]
21. Khorana AA, Kuderer NM, Culakova E. Development and Validation of a predictive model for chemotherapy-associated thrombosis. Blood 2008; 111 (10): 4902–7.
22. Khorana AA. Risk assessment and profilaxis for VTE in cancer patients. Natl Compr Canc Netw 2011; 9: 789–97.
23. Watson HG et al. Guideline on aspects of cancer-related venous thrombosis. Br J Haematol 2015; 170: 640–8.
24. Schulman S, Goldhaber SZ, Kearon C et al. Treatment with dabigatran or warfarin in patients with venous thromboembolism and cancer. Thromb Haemost 2015; 114: 150–7.
25. Prins MH, Lensing AW, Brighton TA et al. Oral rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of symptomatic venous thromboembolism in patients with cancer (EINSTEIN-DVT and EINSTEIN-PE): a pooled subgroup analysis of two randomised controlled trials. Lancet Haematol 2014; 1 (1): e37–46.
26. Vedovati MC, Germini F, Agnelli G, Becattini C. Direct oral anticoagulants in patients with VTE and cancer: a systematic review and meta-analysis. Chest 2015; 147 (2): 475–83.
27. Gerotziafas GT, Mahe I, Elalamy I. New orally active anticoagulant agents for the prevention and treatment of venous thromboembolism in cancer patients. Ther Clin Risk Manag 2014; 10: 423–36.
28. Kearon C, Akl EA, Ornelas J et al. Antithrombotic Therapy for VTE Disease. Chest Guidelines and Expert Panel Report. Chest 2016; 149 (2): 315–52.
29. Gagliardi G, Constine LS, Moiseenko V et al. Radiation Dose-Volume Effects in the Heart. Int J Radiat Oncol Biol Phys 2010; 76 (3; Suppl.): 77–85.
30. Aleman BMP, van den Belt-Dusebout AW, Klokman WJ et al. Long-term cause-specific mortality of patients treated for Hodgkin’s disease. J Clin Oncol 2003; 21: 3431–9.
31. Darby SC, Cutter DJ, Boerma M et al. Radiation-related heart disease: current knowledge and future prospects. Int J Radiat Oncol Biol Phys 2010; 76: 656–65.
32. Wei X, Liu HH, Tucker SL et al. Risk factors for pericardial effusion in inoperable esophageal cancer patients treated with definitive chemoradiation therapy. Int J Radiat Oncol Biol Phys 2008; 70: 707–14.
33. Jaworski C, Mariani JA, Wheeler G, Kaye DM. Cardiac complications of thoracic irradiation. J Am Coll Cardiol 2013; 61: 2319–28.
34. Aleman BM, van den Belt-Dusebout AW, De Bruin ML et al. Late cardiotoxicity after treatment for Hodgkin lymphoma. Blood 2007; 109: 1878–86.
35. Taylor CW et al. Cardiac exposures in breast cancer radiotherapy: 1950’s–1990’s. Int J Radiat Oncol Biol Phys 2007; 69: 1484–95.
36. Cuzick J, Stewart H, Peto R et al. Overview of randomized trials of postoperative adjuvant radiotherapy in breast cancer. Cancer Treat Rep 1987; 71: 15–29.
37. Paszat LF, Mackillop WJ, Groome PA et al. Mortality from myocardial infarction after adjuvant radiotherapy for breast cancer in the surveillance, epidemiology, and end-results cancer registries. J Clin Oncol 1998; 16: 2625–31.
38. Early Breast Cancer Trialists’ Collaborative Group. Effects of radiotherapy and surgery in early breast cancer. An overview of the randomized trials. N Engl J Med 1995; 333 (22): 1444–55.
39. Clarke M, Collins R, Darby S et al. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 366: 2087–106.
40. Giordano SH, Kuo YF, Freeman JL et al: Risk of cardiac death after adjuvant radiotherapy for breast cancer. J Natl Cancer Inst 2005; 97 (6): 419–24.
41. Hooning M, Botma A, Aleman B et al. Long-term risk of cardiovascular disease in 10-year survivors of breast cancer. J Natl Cancer Inst 2007; 99: 365–75.
42. Borger JN, Hooning MJ, Boersma LJ et al. Cardiotoxic effects of tangential breast irradiation in early breast patients: The role of irradiated heart volume. Inst J Radiat Oncol Biol Phys 2007; 69 (4): 1131–8.
43. Darby SC, McGale P, Taylor CW, Peto R. Long-term mortality from heart disease and lung cancer after radiotherapy for early breast cancer: prospective cohort study of about 300,000 women in US SEER cancer registries. Lancet Oncol 2005; 6: 557–65.
44. Early Breast Cancer Trialists Collaborative Group (EBCTCG), Darby S, McGale P, Correa C et al. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet 2011; 378 (9804): 1707–16.
45. Patt DA, Goodwin JS, Kuo YE et al. Cardiac morbidity of adjuvant radiotherapy for breast cancer. J Clin Oncol 2005; 23 (30): 7475–82.
46. Wright GP, Drinane JJ. Left-Sided Breast Irradiation does not Result in Increased Long-Term Cardiac-Related Mortality Among Women Treated with Breast-Conserving Surgery. Ann Surg Oncol 2016, 23: 1117–22.
47. Schultz-Hector S, Trott KR. Radiation-induced cardiovascular diseases: is the epidemiologic evidence compatible with the radiobiologic data. Int J Radiat Oncol Biol Phys 2007; 67: 10–8.
48. Wu W, Masri A, Popovic ZB et al. Long-term survival of patients with radiation heart disease undergoing cardiac surgery: a cohort study. Circulation 2013; 127: 1476–84.
49. Hancock S, Tucker M, Hoppe R. Factors affecting late mortality from heart disease after treatment of Hodgkin’s disease. JAMA 1993; 270: 1949–55.
50. Carver JR, Shapiro CL, Ng A et al. ASCO Cancer Survivorship Expert Panel. American Society of Clinical Oncology clinical evidence review on the ongoing care of adult cancer survivors: cardiac and pulmonary late effects. J Clin Oncol 2007; 25: 3991–4008.
51. Meyer R, Gospodarowicz M, Connors J et al. NCIC Clinical Trials Group, Eastern Cooperative Oncology Group. ABVD alone versus radiation-based therapy in limited-stage Hodgkin’s lymphoma. N Engl J Med 2012; 366: 399–408.
52. Lee CK, Aeppli D, Nierengarten ME. The need for long-term surveillance for patients treated with curative radiotherapy for Hodgkin’s disease: University of Minnesota experience. Int J Radiat Oncol Biol Phys 2000; 48: 169–79.
53. Lancellotti P, Nkomo VT, Badano LP et al. European Society of Cardiology Working Groups on Nuclear Cardiology and Cardiac Computed Tomography and Cardiovascular Magnetic Resonance, American Society of Nuclear Cardiology, Society for Cardiovascular Magnetic Resonance, Society of Cardiovascular Computed Tomography. Expert consensus for multi-modality imaging evaluation of cardiovascular complications of radiotherapy in adults: a report from the European Association of Cardiovascular Imaging and the American Society of Echocardiography. Eur Heart J Cardiovasc Imaging 2013; 14: 721–40.
54. Ridker PM, Buring JE, Rifai N et al. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: The Reynolds score. J Am Med Assoc 2007; 297 (6): 611–9.
55. Darby SC, Ewertz M, McGalle P et al. Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med 2013; 368: 987–98.
56. Marhin W, Wai E, Tyldesley S. Impact of fraction size on cardiac mortality in women treated with tangential radiotherapy for localized breast cancer. Int J Radiat Oncol Biol Phys 2007; 69: 483–89.
57. Shapiro C, Hardenbergh P, Gelman R et al. Cardiac effects of adjuvant doxorubicin and radiation therapy in breast cancer patients. J Clin Oncol 1998; 16: 3493–501.
58. Hull MC, Morris CG, Pepine CJ, Mendenhall NP. Valvular Dysfunction and Carotid, Subclavian, and Coronary Artery Disease in Survivors of Hodgkin Lymphoma Treated With Radiation Therapy. JAMA 2003; 290 (21): 2831–37.
59. Marks LB, Yu X, Prosnitz RG et al. The incidence functional consequences of RT-associated cardiac perfusion defects. Int J Radiat Oncol Biol Phys 2005; 63 (1): 214–23.
60. Van Nimwegen FA, Schaapveld M, Janus CP et al. Cardiovascular disease after Hodgkin lymphoma treatment: 40-year disease risk. JAMA Intern Med 2015; 175: 1007–17.
61. Paszat LF, Mackillop WJ, Groome PA. Mortality from myocardial infarction following postmastectomy radiotherapy for breast cancer: A population-based study in Ontario, Canada. Inst J Radiat Oncol Biol Phys 1999; 43 (2): 755–61.
62. King V, Constine L, Clark D et al. Symptomatic coronary artery disease after mantle irradiation for Hodgkin’s disease. Int J Radiat Oncol Biol Phys 1996; 36: 881–9.
63. Heidenreich P, Kapoor J. Radiation induced heart disease: systemic disorders in heart disease. Heart 2009; 95: 252–8.
64. Harris EE, Correa C, Hwang WT. Late cardiac mortality and morbidity in early-stage breast cancer patients after breast-conservation treatment. J Clin Oncol 2006; 24 (25): 4100–6.
65. Baker JE, Moulder JE, Hopewell JW. Radiation as a risk factor for cardiovascular disease. Antioxid Redox Signal 2011; 15: 1945–56.
66. Taunk NK, Haffty BG, Kostis JB, Goyal S. Radiation-induced heart disease: pathologic abnormalities and putative mechanisms. Front Oncol 2015; 5: 39.
67. Boerma M, Hauer-Jensen M. Preclinical research into basic mechanisms of radiation-induced heart disease. Cardiol Res Pract 2011. DOI: 10.4061/2011/858262
68. Stewart F, Hoving S, Russell N. Vascular damage as an underlying mechanism of cardiac and cerebral toxicity in irradiated cancer patients. Radiat Res 2010; 174: 865–9.
69. Yusuf S, Sami S, Daher I. Radiation-induced heart disease: a clinical update. Cardiol Res Pract 2011; Article ID 317659.
70. Stewart F, Heeneman S, Te Poele J et al. Ionizing radiation accelerates the development of atherosclerotic lesions in ApoE2/2 mice and predisposes to an inflammatory plaque phenotype prone to hemorrhage. Am J Pathol 2006; 168: 649–58.
71. Hardenbergh PH, Munley MT, Bentel GC et al. Cardiac perfusion changes in patients treated for breast cancer with radiation therapy and doxorubicin: preliminary results. Int J Radiat Oncol Biol Phys 2001; 49: 1023–8.
72. Gomez DR, Yusuf SW, Munsell M et al. A Prospective Exploratory Analysis of Cardiac Biomarkers and Electrocardiogram Abnormalities in Patients Receiving Thoracic Radiation Therapy with High-Dose Heart Exposure. J Thorac Oncol 2014; 9 (10): 1554–60.
73. Erven K, Florian A, Slagmolen P, Sweldens C et al. Subclinical cardiotoxicity detected by strain rate imaging up to 14 months after breast radiation therapy. Int J Radiat Oncol Biol Phys 2013; 85 (5): 1172–8.
74. Armstrong GT, Joshi VM, Ness KK et al. Comprehensive echocardiographic detection of treatment-related cardiac dysfunction in adult survivors of childhood cancer: results from the St. Jude Lifetime Cohort Study. J Am Coll Cardiol 2015; 65: 2511–22.
75. Nagueh S, Appleton C, Gillebert T et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography. Eur J Echocardiogr 2009; 10: 165–93.
76. Constine L, Schwartz R, Savage D et al. Cardiac function, perfusion, and morbidity in irradiated long-term survivors of Hodgkin’s disease. Int J Radiat Oncol Biol Phys 1997; 39: 897–906.
77. DePasquale EC, Nasir K, Jacoby DL. Outcomes of adults with restrictive cardiomyopathy after heart transplantation. J Heart Lung Transplant 2012; 31 (12): 1269–75.
78. McGale P, Darby SC, Hall P et al. Incidence of heart disease in 35,000 women treated with radiotherapy for breast cancer in Denmark and Sweden. Radiother Oncol 2011; 100: 167–75.
79. Virmani R, Farb A, Carter AJ, Jones RM. Comparative pathology: radiation-induced coronary artery disease in man and animals. Semin Interv Cardiol 1998; 3: 163–72.
80. Brosius FC 3rd, Waller BF, Roberts WC. Radiation heart disease. Analysis of 16 young (aged 15 to 33 years) necropsy patients who received over 3,500 rads to the heart. Am J Med 1981; 70: 519–530.
81. Veinot JP, Edwards WD. Pathology of radiation-induced heart disease: a surgical and autopsy study of 27 cases. Hum Pathol 1996; 27: 766–73.
82. McEniery PT, Dorosti K, Schiavone WA et al. Clinical and angiographic features of coronary artery disease after chest irradiation. Am J Cardiol 1987; 60: 1020–4.
83. Hering D, Faber L, Horstkotte D. Echocardiographic features of radiation-associated valvular disease. Am J Cardiol 2003; 92: 226–30.
84. Brouwer CA, Postma A, Hooimeijer HL et al. Endothelial damage in long-term survivors of childhood cancer. J Clin Oncol 2013; 31: 3906–13.
85. Correa CR, Litt HI, Hwang WT et al. Coronary artery findings after left-sided compared with right-sided radiation treatment for earlystage breast cancer. J Clin Oncol 2007; 25: 3031–7.
86. Storey MR, Munden R, Strom EA et al. Coronary artery dosimetry in intact left breast irradiation. Cancer J 2001; 7: 492–7.
87. Van Nimwegen FA, Schaapveld M, Cutter DJ et al. Radiation dose-response relationship for risk of coronary heart disease in survivors of Hodgkin lymphoma. J Clin Oncol 2016; 34: 235–43.
88. De Haas EC, Oosting SF, Lefrandt JD et al. The metabolic syndrome in cancer survivors. Lancet Oncol 2010; 11: 193–203.
89. Oeffinger KC, Mertens AC, Sklar CA et al. Childhood Cancer Survivor Study. Chronic health conditions in adult survivors of childhood cancer. N Engl J Med 2006; 355: 1572–82.
90. Orzan F, Brusca A, Conte MR et al. Severe coronary artery disease after radiation therapy of the chest and mediastinum: clinical presentation and treatment. Br Heart J 1993; 69: 496–500.
91. Vijayakumar S, Rosenberg I, Spelbring D, Brandt T. Estimation of doses to heart, coronary arteries, and spinal cord in mediastinal irradiation for Hodgkin’s disease. Med Dosim 1991; 16: 237–41.
92. Prosnitz RG, Hubbs JL, Evans ES et al. Prospective assessment of radiotherapy-associated cardiac toxicity in breast cancer patients: analysis of data 3 to 6 years after treatment. Cancer 2007; 110: 1840–50.
93. Gyenes G, Fornander T, Carlens P et al. Detection of radiation-induced myocardial damage by technetium-99 m sestamibi scintigraphy. Eur J Nucl Med 1997; 24: 286–92.
94. Haugnes HS, Wethal T, Aass N et al. Cardiovascular risk factors and morbidity in long-term survivors of testicular cancer: a 20-year follow-up study. J Clin Oncol 2010; 28: 4649–57.
95. Malanca M, Cimadevilla C, Brochet E et al. Radiotherapy-induced mitral stenosis: a three-dimensional perspective. J Am Soc Echocardiogr 2010; 23 (108): e101–102.
96. Plana JC, Galderisi M, Barac A et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging 2014; 15: 1063–93.
97. Carlson RG, Mayfield WR, Normann S, Alexander JA. Radiation-associated valvular disease. Chest 1991; 99: 538–45.
98. Glanzmann C, Huguenin P, Lutolf UM et al. Cardiac lesions after mediastinal irradiation for Hodgkin’s disease. Radiother Oncol 1994; 30: 43–54.
99. Brand MD, Abadi CA, Aurigemma GP et al. Radiation-associated valvular heart disease in Hodgkin’s disease is associated with characteristic thickening and fibrosis of the aortic-mitral curtain. J Heart Valve Dis 2001; 10: 681–5.
100. Katz NM, Hall AW, Cerqueira MD. Radiation induced valvulitis with late leaflet rupture. Heart 2001; 86: E20.
101. Pohjola-Sintonen S, Totterman KJ, Salmo M, Siltanen P. Late cardiac effects of mediastinal radiotherapy in patients with Hodgkin’s disease. Cancer 1987; 60: 31–7.
102. Cutter DJ, Schaapveld M, Darby SC et al. Risk of valvular heart disease after treatment for Hodgkin lymphoma. J Natl Cancer Inst 2015; 107: djv008.
103. Groarke JD, Nguyen PL, Nohria A et al. Cardiovascular complications of radiation therapy for thoracic malignancies: the role for noninvasive imaging for detection of cardiovascular disease. Eur Heart J 2014; 35: 612–23.
104. Vahanian A, Alfieri O, Andreotti F et al. Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC), European Association for Cardio-Thoracic Surgery (EACTS), Guidelines on the management of valvular heart disease (version 2012). Eur Heart J 2012; 33: 2451–96.
105. De Bruin ML, Dorresteijn LD, van’t Veer MB et al. Increased risk of stroke and transient ischemic attack in 5-year survivors of Hodgkin lymphoma. J Natl Cancer Inst 2009; 101: 928–37.
106. Yuan H, Gaber MW, Boyd K et al. Effects of fractionated radiation on the brain vasculature in a murine model: blood-brain barrier permeability, astrocyte proliferation, and ultrastructural changes. Int J Radiat Oncol Biol Phys 2006; 66: 860–6.
107. Louis EL, McLoughlin MJ, Wortzman G. Chronic damage to medium and large arteries following irradiation. J Can Assoc Radiol 1974; 25: 94–104.
108. Fajardo LF. The pathology of ionizing radiation as defined by morphologic patterns. Acta Oncol 2005; 44: 13–22.
109. Jurado JA, Bashir R, Burket MW. Radiation-induced peripheral artery disease. Catheter Cardiovasc Interv 2008; 72: 563–8.
110. Tendera M, Aboyans V, Bartelink ML et al. European Stroke Organisation, ESC Committee for Practice Guidelines. ESC Guidelines on the diagnosis and treatment of peripheral artery diseases: Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries: the Task Force on the Diagnosis and Treatment of Peripheral Artery Diseases of the European Society of Cardiology (ESC). Eur Heart J 2011; 32: 2851–906.
111. Fokkema M, den Hartog AG, Bots ML et al. Stenting versus surgery in patients with carotid stenosis after previous cervical radiation therapy: systematic review and meta-analysis. Stroke 2012; 43: 793–801.
112. Gujral DM, Shah BN, Chahal NS et al. Clinical features of radiation-induced carotid atherosclerosis. Clin Oncol (R Coll Radiol) 2014; 26: 94–102.
113. Adler Y, Charron P, Imazio M et al. European Society of Cardiology. 2015 ESC Guidelines for the diagnosis and management of pericardial diseases: the Task Force for the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology (ESC). Endorsed by: the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 2015; 36: 2921–64.
114. Stewart JR, Fajardo LF, Gillette SM, Constine LS. Radiation injury to the heart. Int J Radiat Oncol Biol Phys 1995; 31: 1205–11.
115. Applefeld MM, Wiernik PH. Cardiac disease after radiation therapy for Hodgkin’s disease: analysis of 48 patients. Am J Cardiol 1983; 51: 1679–81.
116. Maisch B, Ristic A, Pankuweit S. Evaluation and Management of Pericardial Effusion in Patients with Neoplastic Disease. Prog Cardiovasc Dis 2010; 53 (2): 157–63.
117. Welch TD, Ling LH, Espinosa RE et al. Echocardiographic diagnosis of constrictive pericarditis: Mayo Clinic criteria. Circ Cardiovasc Imaging 2014; 7: 526–34.
118. Bertog SC, Thambidorai SK, Parakh K et al. Constrictive Pericarditis: Etiology and Cause-Specific Survival After Pericardiectomy. J Am Coll Cardiol 2004; 43: 1445–52.
119. Ness KK, Armstrong GT. Screening for cardiac autonomic dysfunction among Hodgkin lymphoma survivors treated with thoracic radiation. J Am Coll Cardiol 2015; 65: 584–5.
120. Bentzen SM, Constine LS, Deasy JO. Quantitative Analyses of Normal Tissue Effects in the Clinic (QUANTEC): an introduction to the scientific issues. Int J Radiat Oncol Biol Phys 2010; 76 (Suppl. 3): S3–9.
121. Prosnitz RG, Chen YH, Marks LB. Cardiac toxicity following thoracic radiation. Semin Oncol 2005; 32 (2; Suppl. 3): S71–S80.
122. Louwe RJ, Wendling M, van Herk MB, Mijnheer BJ. Three-dimensional heart dose reconstruction to estimate normal tissue complication probability after breast irradiation using portal dosimetry. Med Phys 2007; 34: 1354–63.
123. McDonald MW, Godette KL, Whitaker DJ et al. Three-year outcomes of breast. intensity-modulated radiation therapy with. simultaneous integrated boost. Int J Radiat Oncol Biol Phys 2010; 77: 523–30.
124. Tan W, Liu D, Xue C et al. Anterior myocardial territory may replace the heart as organ at risk in intensity-modulated radiotherapy for left-sided breast cancer. Int J Radiat Oncol Biol Phys 2012; 82: 1689–97.
125. Baycan D, Karacetin D, Balkanay AY et al. Field-in-field IMRT versus 3D-CRT of the breast. Cardiac vessels, ipsilateral lung, and contralateral breast absorbed doses in patients with left-sided lumpectomy: a dosimetric comparison. Jpn J Radiol 2012; 30: 819–23.
126. Bruzzaniti V, Abate A, Pinnaro P et al. Dosimetric and clinical advantages of deep inspiration breath-hold (DIBH) during radiotherapy of breast cancer. J Exp Clin Cancer Res 2013; 32: 88.
127. Xu Q, Chen Y, Grimm J et al. Dosimetric investigation of accelerated partial breast irradiation (APBI) using CyberKnife. Med Phys 2012; 39: 6621–8.
128. Bartlett FR, Colgan RM, Donovan EM et al. HeartSpare Study (Stage IB): randomised comparison of a voluntary breath-hold technique and prone radiotherapy after breast conserving surgery. Radiother Oncol 2015; 114: 66–72.
129. Utehina O. Healthy tissue sparing postoperative radiotherapy for treatment of early stage breast cancer. Summary of the doctoral thesis. Riga, 2009; p. 32.
130. Trofimova O.P., Cheban O.I., Mikhina Z.P. Kardiovaskuliarnye oslozhneniia u bolnykh RMZh posle organosokhraniaiushchego lecheniia. Med. radiologiia i radiatsionnaia bezopasnost. 2015; 1: 33–8. [in Russian]
131. Piepoli MF, Hoes AW, Agewall S et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. DOI: 10.1093/eurheartj/ehw106
132. Ewer MS, Lenihan DJ. Left ventricular ejection fraction and cardiotoxicity: is our ear really to the ground? J Clin Oncol 2008; 26: 1201–3.
133. Lenihan DJ, Cardinale DM. Late cardiac effects of cancer treatment. J Clin Oncol 2012; 30: 3657–64.
134. Heidenreich PA, Hancock SL, Lee BK et al. Asymptomatic cardiac disease following mediastinal irradiation. J Am Coll Cardiol 2003; 42: 743–9.
135. Koppelmans V, Vernooij MW, Boogerd W et al. Prevalence of cerebral small-vessel disease in long-term breast cancer survivors exposed to both adjuvant radiotherapy and chemotherapy. J Clin Oncol 2015; 33: 588–93.
136. Copeland KA, Hosmane VR, Jurkovitz C et al. Frequency of severe valvular disease caused by mediastinal radiation among patients undergoing valve surgery in a community-based, regional academic medical center. Clin Cardiol 2013; 36: 217–21.
137. Machann W, Beer M, Breunig M et al. Cardiac magnetic resonance imaging findings in 20-year survivors of mediastinal radiotherapy for Hodgkin’s disease. Int J Radiat Oncol Biol Phys 2011; 79: 1117–23.

И.Е.Чазова1, С.А.Тюляндин2, М.В.Виценя*1, Е.П.Панченко1, Ю.А.Федоткина1, М.Г.Полтавская3, М.Ю.Гиляров3, Т.В.Мартынюк1, А.Г.Овчинников1, М.Б.Стенина2, О.П.Трофимова2,4, Ф.Т.Агеев1

1 Институт клинической кардиологии им. А.Л.Мясникова ФГБУ «Национальный медицинский исследовательский центр кардиологии» Минздрава России. 121552, Россия, Москва, ул. 3-я Черепковская, д. 15а;
2 ФГБУ «Национальный медицинский исследовательский центр онкологии им. Н.Н.Блохина» Минздрава России. 115478, Россия, Москва, Каширское ш., д. 23;
3 ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М.Сеченова» Минздрава России. 119991, Россия, Москва, ул. Трубецкая, д. 8, стр. 1;
4 ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава России. 125993, Россия, Москва, ул. Баррикадная, д. 2/1
*marinavitsenya@gmail.com

________________________________________________

I.Ye.Chazova1, S.A.Tyulyandin2, M.V.Vitsenia*1, E.P.Panchenko1, Yu.A.Fedotkina1, M.G.Poltavskaya3, M.Yu.Gilyarov3, T.V.Martynyuk1, A.G.Ovchinnikov1, M.B.Stenina2, O.P.Trophimova2, 4, F.T.Ageev1

1 A.L.Myasnikov Institute of Clinical Cardiology National Medical Research Center of Cardiology of the Ministry of Health of the Russian Federation. 121552, Russian Federation, Moscow, ul. 3-ia Cherepkovskaia, d. 15a;
2 N.N.Blokhin National Medical Research Center of Oncology of the Ministry of Health of the Russian Federation. 115478, Russian Federation, Moscow, Kashirskoe sh., d. 23;
3 I.M.Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation. 119991, Russian Federation, Moscow, ul. Trubetskaia, d. 8, str. 2;
4 Russian Medical Academy of Continuous Professional Education of the Ministry of Health of the Russian Federation. 125993, Russian Federation, Moscow, ul. Barrikadnaia, d. 2/1
*marinavitsenya@gmail.com